Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)

Scientific Officer of Biodexa Pharmaceuticals PLC, expressed his satisfaction with the study's results. He emphasized that the study provided valuable insights into the safety and efficacy of intra-tumoral administration of MTX110 via CED. The success of this study has led to a follow-up Phase I study at Columbia University.